Skip to content
value.today
Abeona Therapeutics Inc. logo

Abeona Therapeutics Inc.

ABEO
$261 Mmarket cap on Oct 30, 2026+82.2% since Jan 2024
Compare
World rank
#15,315
Revenue
$6 M
For year ending December-2025
Net income
$71 M
1223.0% margin
SEC filing
Employees
226
As of December 31, 2025
SEC filing

Abeona Therapeutics Inc. in brief

Abeona Therapeutics Inc. is a listed company in the Biotechnology industry, based in Texas, USA. It was founded in 1974. Its market value was $261 M on 30 October 2026, which makes it the 15,315th largest listed company in the world and the 2,985th largest in the USA on this site. In the year to December 2025 it had sales of $6 M and a net profit of $71 M. It employs about 226 people and Vishwas Seshadri is its chief executive. Its largest product and service lines by sales in 2025 were License (58%). Its shares trade under the symbol ABEO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Abeona Therapeutics Inc.

ZEVASKYN® is manufactured at our current Good Manufacturing Practices manufacturing facility in Cleveland, Ohio. Treatments are available through ZEVASKYN® qualified treatment centers, a network of centers that are selected based on their expertise in cell and gene therapy and trained to administer ZEVASKYN®. As of March 2026, we have activated 4 qualified treatment centers and are in discussions with additional centers as we continue to expand the ZEVASKYN® qualified treatment network.

The Company’s development portfolio also features adeno-associated virus-based gene therapies designed to treat ophthalmic diseases with high unmet need using novel AIM™ capsids. Abeona’s novel AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

From the company's annual report filed with the US SEC: read the report

Abeona Therapeutics Inc. timeline

6 events, 1974–2020
  1. 1974
  2. 🏁
    · approximate
    Founded
  3. 1995
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 1996
  6. ✎
    Renamed Access Pharmaceuticals Inc
    Formerly Chemex Pharmaceuticals Inc.
  7. 2014
  8. ✎
    Renamed Plasmatech Biopharmaceuticals Inc
    Formerly Access Pharmaceuticals Inc.
  9. 2015
  10. ✎
    Renamed Abeona Therapeutics Inc.
    Formerly Plasmatech Biopharmaceuticals Inc.
  11. 2020
  12. 💰
    Record revenue of $10 million
    FY2020, the highest of the 6 years on record.

Events of Abeona Therapeutics Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$92 M$184 M$276 M$368 M2020202120222023202420252026

World rank over time

▼ down 1,154 places since 2020
2020-01-01: #14202#14,20220202021-01-01: #16418#16,41820212022-01-07: #26314#26,31420222022-12-25: #26314#26,31420222023-07-30: #23013#23,01320232024-01-05: #19647#19,64720242026-03-08: #8554#8,55420262026-08-01: #13728#13,72820262026-10-13: #15133#15,13320262026-10-30: #15356#15,3562026

Rank in USA: #2,945 (Jan 2020) · #3,401 (Jan 2021) · #4,954 (Jan 2022) · #4,897 (Dec 2022) · #4,425 (Jul 2023) · #3,469 (Jan 2024) · #1,579 (Mar 2026) · #2,774 (Aug 2026) · #2,931 (Oct 2026) · #2,989 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
3.7×
Price / sales
44.8×
Price / book
1.6×
Free cash flow yield
-32.4%
Net margin
1223.0%
Operating margin
-1536.9%
Return on equity
44.7%
Liabilities / assets
27.5%
Net debt
$-58M
Revenue growth
+66.3%
R&D / revenue
460.7%
Revenue per employee
$26 K
Profit per employee
$315 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $3M, net income $-57M$3MFY18Fiscal year ending Dec 2019: revenue —, net income $-76M—FY19Fiscal year ending Dec 2020: revenue $10M, net income $-84M$10MFY20Fiscal year ending Dec 2021: revenue $3M, net income $-85M$3MFY21Fiscal year ending Dec 2022: revenue $1M, net income $-40M$1MFY22Fiscal year ending Dec 2023: revenue $4M, net income $-54M$4MFY23Fiscal year ending Dec 2024: revenue —, net income $-64M—FY24Fiscal year ending Dec 2025: revenue $6M, net income $71M$6MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$6M—$-89M$71M1223.0%
Dec 2024——$-64M$-64M—
Dec 2023$4M+148.2%$-47M$-54M-1548.3%
Dec 2022$1M-53.0%$-51M$-40M-2815.6%
Dec 2021$3M-70.0%$-90M$-85M-2831.3%
Dec 2020$10M—$-81M$-84M-842.3%
Dec 2019——$-77M$-76M—
Dec 2018$3M—$-58M$-57M-1889.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-76M$8M$-84M$1.01—
Dec 2024$-56M$2M$-58M$-1.55—
Dec 2023$-37M$0M$-37M$-2.53—
Dec 2022$-43M$0M$-44M$-5.53—
Dec 2021$-66M$4M$-70M$-0.86—
Dec 2020$-35M$1M$-36M$-0.91—
Dec 2019$-63M$6M$-69M$-1.51—
Dec 2018$-39M$9M$-48M$-1.19—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-9M—Dec ’24Three months to Mar 2025: revenue —, net income $-12M—Mar ’25Three months to Jun 2025: revenue $0M, net income $109M$0MJun ’25Three months to Sep 2025: revenue —, net income $-5M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-20M—Dec ’25Three months to Mar 2026: revenue $9M, net income $-17M$9MMar ’26Three months to Jun 2026: revenue $11M, net income $-20M$11MJun ’26Three months to Sep 2026: revenue $13M, net income $-5M$13MSep ’26

Latest quarter to Sep 2026: revenue $13M, net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Abeona Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$6 M
Operating income
$-89 M
Net income
$71 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$220 M
Total liabilities
$60 M
Total equity
$159 M

As of December-2025

Top 100 institutional investors in Abeona Therapeutics Inc.#

As of Sep 30, 2026
115 institutions held 40.8 M shares (about 71.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 46.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Abeona Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Nantahala Capital Management, LLC5,410,643-4,862,337 (-47.33%)9.47%$28 MNov 13, 2026
2Cable Car Capital, LP3,600,000+592,671 (+19.71%)6.30%$19 MNov 16, 2026
3BlackRock, Inc.3,376,695+24,221 (+0.72%)5.91%$18 MNov 13, 2026
4Rubric Capital Management LP3,339,707+2,730,936 (+448.60%)5.84%$18 MNov 16, 2026
5AIGH Capital Management LLC2,900,000-87,000 (-2.91%)5.07%$15 MNov 2, 2026
6Vanguard Capital Management LLC2,137,768-73,665 (-3.33%)3.74%$11 MNov 13, 2026
7J. Goldman & Co LP1,517,152+838,979 (+123.71%)2.65%$8 MNov 16, 2026
8AWM Investment Company, Inc.1,487,130+1,000 (+0.07%)2.60%$8 MNov 13, 2026
9Kennedy Capital Management LLC1,330,788+90,717 (+7.32%)2.33%$7 MNov 13, 2026
10Geode Capital Management, LLC1,325,534+64,444 (+5.11%)2.32%$7 MNov 6, 2026
11Goldman Sachs Group Inc1,159,504-65,302 (-5.33%)2.03%$6 MNov 16, 2026
12State Street Corp1,051,382+11,154 (+1.07%)1.84%$6 MNov 12, 2026
13Propel Bio Management, LLC956,007-27,063 (-2.75%)1.67%$5 MNov 13, 2026
14Citigroup Inc874,649+326,349 (+59.52%)1.53%$5 MNov 4, 2026
15Bank Of America Corp /de/730,211+357,805 (+96.08%)1.28%$4 MNov 16, 2026
16Silverarc Capital Management, LLC693,441+83,034 (+13.60%)1.21%$4 MNov 12, 2026
17Barclays PLC602,576+246,149 (+69.06%)1.05%$3 MNov 6, 2026
18Nan Fung Trinity (HK) LTD552,270-404,500 (-42.28%)0.97%$3 MNov 6, 2026
19Woodline Partners LP551,837New0.97%$3 MNov 16, 2026
20Northern Trust Corp538,350-14,280 (-2.58%)0.94%$3 MNov 16, 2026
21Panagora Asset Management Inc527,147+118,072 (+28.86%)0.92%$3 MNov 12, 2026
22National Bank Of Canada /fi/500,0000 (0.00%)0.87%$3 MNov 16, 2026
23Morgan Stanley442,801+77,242 (+21.13%)0.77%$2 MNov 13, 2026
24Diametric Capital, LP403,436-351,585 (-46.57%)0.71%$2 MNov 16, 2026
25Vanguard Fiduciary Trust Co334,779-13,239 (-3.80%)0.59%$2 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Abeona Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Portfolio Management LLC313,394+21,741 (+7.45%)0.55%$2 MNov 13, 2026
27Stonepine Capital Management, LLC282,016-275,268 (-49.39%)0.49%$1 MNov 13, 2026
28Simplify Asset Management Inc.276,333-69,083 (-20.00%)0.48%$1 MOct 27, 2026
29ExodusPoint Capital Management, LP242,174+29,849 (+14.06%)0.42%$1 MNov 16, 2026
30Bank of New York Mellon Corp207,526+3,280 (+1.61%)0.36%$1 MNov 5, 2026
31UBS Group AG205,312-17,967 (-8.05%)0.36%$1 MNov 10, 2026
32Corient Private Wealth LP198,677+108,769 (+120.98%)0.35%$1 MNov 16, 2026
33Dimensional Fund Advisors LP194,201+159,830 (+465.01%)0.34%$1 MNov 4, 2026
34Y-Intercept (Hong Kong) Ltd168,334+95,961 (+132.59%)0.29%$1 MOct 16, 2026
35Millennium Management LLC163,890-47,445 (-22.45%)0.29%$1 MNov 16, 2026
36Charles Schwab Investment Management Inc136,043+15,529 (+12.89%)0.24%$1 MNov 16, 2026
37Two Sigma Investments, LP124,674+43,937 (+54.42%)0.22%$1 MNov 16, 2026
38SEI Investments Co112,995+7,435 (+7.04%)0.20%$1 MNov 10, 2026
39Palo Alto Investors LP108,8650 (0.00%)0.19%$1 MNov 16, 2026
40Nuveen, LLC94,148+11,522 (+13.94%)0.16%$0 MNov 10, 2026
41Birchview Capital, LP90,700New0.16%$0 MNov 13, 2026
42Pale Fire Capital SE76,844-5,101 (-6.22%)0.13%$0 MNov 13, 2026
43American Century Companies Inc74,056+27,641 (+59.55%)0.13%$0 MNov 12, 2026
44LPL Financial LLC70,419+624 (+0.89%)0.12%$0 MNov 6, 2026
45BNP Paribas Financial Markets69,924+62,934 (+900.34%)0.12%$0 MNov 12, 2026
46UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC60,453+57,041 (+1671.78%)0.11%$0 MNov 16, 2026
47Jain Global LLC60,095+31,210 (+108.05%)0.11%$0 MNov 16, 2026
48Caption Management, LLC60,000New0.10%$0 MNov 16, 2026
49Rhumbline Advisers55,388-1,363 (-2.40%)0.10%$0 MNov 10, 2026
50Rangeley Capital, LLC51,300-6,800 (-11.70%)0.09%$0 MNov 16, 2026
51Diadema Partners LP51,117New0.09%$0 MNov 16, 2026
52Atom Investors LP50,717+25,847 (+103.93%)0.09%$0 MNov 16, 2026
53Harbor Capital Advisors, Inc.50,035+11,747 (+30.68%)0.09%$0 MOct 22, 2026
54Seven Fleet Capital Management LP48,745New0.09%$0 MNov 16, 2026
55Campbell & CO Investment Adviser LLC47,834New0.08%$0 MNov 13, 2026
56AQR Capital Management LLC42,734-24,329 (-36.28%)0.07%$0 MNov 16, 2026
57FMR LLC41,457-97,040 (-70.07%)0.07%$0 MNov 10, 2026
58Deutsche Bank AG\41,381-6,177 (-12.99%)0.07%$0 MNov 6, 2026
59Price T Rowe Associates Inc /MD/39,023+6,432 (+19.74%)0.07%$0 MNov 16, 2026
60Alliancebernstein L.P.37,940-10,010 (-20.88%)0.07%$0 MNov 16, 2026
61Wealth Effects LLC30,950+3,700 (+13.58%)0.05%$0 MOct 23, 2026
62Creative Planning28,746+8,243 (+40.20%)0.05%$0 MNov 2, 2026
63Prelude Capital Management, LLC28,304-27,634 (-49.40%)0.05%$0 MNov 16, 2026
64Russell Investments Group, Ltd.26,902-1,515 (-5.33%)0.05%$0 MNov 6, 2026
65Persistent Asset Partners Ltd26,010+265 (+1.03%)0.05%$0 MNov 13, 2026
66Jpmorgan Chase & Co25,932-24,573 (-48.65%)0.05%$0 MNov 12, 2026
67MetLife Investment Management, LLC24,7660 (0.00%)0.04%$0 MNov 16, 2026
68Riverwater Partners LLC24,3040 (0.00%)0.04%$0 MNov 3, 2026
69Aigen Investment Management, LP23,871New0.04%$0 MNov 16, 2026
70Invesco Ltd.22,265-1,459 (-6.15%)0.04%$0 MNov 12, 2026
71MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.21,193+1,083 (+5.39%)0.04%$0 MNov 16, 2026
72Pinnacle Financial Group, Inc.19,000—0.03%$0 MNov 16, 2026
73Vanguard Global Advisers, LLC18,810+202 (+1.09%)0.03%$0 MNov 13, 2026
74Citadel Advisors LLC16,898-242,503 (-93.49%)0.03%$0 MNov 16, 2026
75Legato Capital Management LLC16,8300 (0.00%)0.03%$0 MNov 10, 2026
76Manufacturers Life Insurance Company, The13,615+1,371 (+11.20%)0.02%$0 MNov 13, 2026
77Natixis13,340-6,291 (-32.05%)0.02%$0 MNov 6, 2026
78Squarepoint Ops LLC12,550New0.02%$0 MNov 9, 2026
79Aries Wealth Management12,5000 (0.00%)0.02%$0 MOct 23, 2026
80Public Employees Retirement System Of Ohio11,938New0.02%$0 MNov 16, 2026
81D. E. Shaw & Co., Inc.11,622-45,478 (-79.65%)0.02%$0 MNov 16, 2026
82Police & Firemen's Retirement System of New Jersey11,0050 (0.00%)0.02%$0 MNov 9, 2026
83Brevan Howard Capital Management LP10,939New0.02%$0 MNov 16, 2026
84MAI Capital Management10,333+2,413 (+30.47%)0.02%$0 MNov 12, 2026
85Savant Capital, LLC10,318New0.02%$0 MNov 6, 2026
86Tower Research Capital LLC (TRC)10,290+6,238 (+153.95%)0.02%$0 MNov 16, 2026
87Wells Fargo & Company/mn8,933-27,655 (-75.58%)0.02%$0 MNov 16, 2026
88Global Retirement Partners, LLC4,978+4,536 (+1026.24%)0.01%$0 MNov 10, 2026
89Allworth Financial LP4,813+161 (+3.46%)0.01%$0 MNov 17, 2026
90Ameritas Investment Partners, Inc.4,4590 (0.00%)0.01%$0 MNov 13, 2026
91Legal & General Group Plc3,9750 (0.00%)0.01%$0 MNov 16, 2026
92PNC Financial Services Group, Inc.2,864+2,295 (+403.34%)0.01%$0 MNov 6, 2026
93Nisa Investment Advisors, LLC2,571-2,000 (-43.75%)0.00%$0 MOct 20, 2026
94Royal Bank Of Canada2,349-1,227 (-34.31%)0.00%$0 MNov 16, 2026
95GAMMA Investing LLC2,012+261 (+14.91%)0.00%$0 MOct 8, 2026
96Arax Advisory Partners1,829-1,866 (-50.50%)0.00%$0 MNov 12, 2026
97New York State Common Retirement Fund1,7000 (0.00%)0.00%$0 MNov 17, 2026
98Osaic Holdings, Inc.1,3610 (0.00%)0.00%$0 MNov 12, 2026
99Rockefeller Capital Management L.P.1,2500 (0.00%)0.00%$0 MNov 13, 2026
100Jones Financial Companies Lllp1,0000 (0.00%)0.00%$0 MNov 13, 2026

All 115 institutional investors, with who bought and sold →

Mutual funds holding Abeona Therapeutics Inc.#

77 funds hold shares worth $40 M (about 11.4% of the company). Since their previous reports 39 added shares and 16 sold, buying $3 M net.
Mutual funds holding Abeona Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.53 M$9 M2.7%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.19 M$7 M2.1%<0.01%+3.0%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.627,769$4 M1.1%<0.01%+12%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC478,770$3 M0.84%<0.01%+4.9%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors409,560$3 M0.72%0.02%+1553%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC263,003$2 M0.46%<0.01%−3.2%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.235,632$1 M0.41%<0.01%+9.1%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors145,114$1 M0.25%0.06%+26%Jun 30, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC133,069$1 M0.23%0.01%−31%Jun 30, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors119,122$1 M0.21%<0.01%+2.3%Jun 30, 2026
🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc.115,525$1 M0.20%0.10%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.105,082$1 M0.18%<0.01%+2.0%Jul 31, 2026
🇺🇸 WisdomTree U.S. SmallCap FundWisdomTree Asset Management, Inc.95,434$1 M0.17%0.08%−2.3%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC98,619$1 M0.17%<0.01%no changeMay 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC75,671$0 M0.13%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC77,084$0 M0.13%<0.01%+6.2%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC60,909$0 M0.11%0.02%+1556%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC56,719$0 M0.10%<0.01%no changeJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC50,057$0 M0.09%<0.01%no changeJun 30, 2026
🇺🇸 Harbor Human Capital Factor US Small Cap ETFHarbor Capital Advisors, Inc.38,309$0 M0.07%0.14%+8.5%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.40,172$0 M0.07%0.01%+6.8%May 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust33,384$0 M0.06%<0.01%+276%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC32,763$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation29,500$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.27,928$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC26,610$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.26,710$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.26,337$0 M0.05%<0.01%+71%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.23,850$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.22,200$0 M0.04%<0.01%+57%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC20,862$0 M0.04%<0.01%+9.0%Jul 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC20,082$0 M0.04%<0.01%+9.3%Jul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC20,045$0 M0.04%0.01%+100%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.19,845$0 M0.03%<0.01%+6.8%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC18,970$0 M0.03%<0.01%+112%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC18,970$0 M0.03%<0.01%+112%Jun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP16,656$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company16,352$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.14,806$0 M0.03%0.02%−4.5%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC14,339$0 M0.03%<0.01%−2.1%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC11,637$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC9,791$0 M0.02%0.03%+20%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC9,363$0 M0.02%<0.01%+11%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC8,352$0 M0.01%0.01%+7.3%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC8,480$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS8,326$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC7,346$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC6,684$0 M0.01%0.01%+32%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.6,680$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.6,662$0 M0.01%<0.01%+31%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC6,400$0 M0.01%<0.01%+1220%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.5,794$0 M0.01%<0.01%+4.6%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC5,553$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC5,114$0 M<0.01%<0.01%+39%Jul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC4,715$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management4,459$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION4,700$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.4,446$0 M<0.01%<0.01%+161%May 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS3,834$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC3,668$0 M<0.01%<0.01%+9.2%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC3,618$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC3,220$0 M<0.01%<0.01%+29%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.3,341$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC2,915$0 M<0.01%<0.01%+1493%Jul 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC2,912$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC2,159$0 M<0.01%<0.01%+14%May 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,913$0 M<0.01%<0.01%−45%Jun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC1,704$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,706$0 M<0.01%<0.01%−37%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,688$0 M<0.01%<0.01%−38%May 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,554$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,383$0 M<0.01%<0.01%+23%Jun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC1,404$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,089$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC916$0 M<0.01%<0.01%−3.1%Jun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.509$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC272$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 77 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Abeona Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$34 K
1 purchase, 1 insider
Sold, 12 months
$3.5 M
37 sales, 9 insiders
Net, 12 months
-$3.5 M
open market only
Insiders on file
30
since
$102 K-$847 K$0Jan 2024: bought $0 (0 trades), sold $36 K (1 trades)Jan 24Feb 2024: bought $88 K (1 trades), sold $0 (0 trades)Apr 2024: bought $102 K (4 trades), sold $0 (0 trades)May 2024: bought $52 K (1 trades), sold $0 (0 trades)MayJun 2024: bought $0 (0 trades), sold $233 K (2 trades)Jan 2025: bought $0 (0 trades), sold $42 K (2 trades)Mar 2025: bought $0 (0 trades), sold $120 K (1 trades)MarMay 2025: bought $0 (0 trades), sold $58 K (2 trades)Jun 2025: bought $0 (0 trades), sold $534 K (3 trades)Jul 2025: bought $0 (0 trades), sold $838 K (8 trades)JulAug 2025: bought $0 (0 trades), sold $143 K (2 trades)Sep 2025: bought $0 (0 trades), sold $338 K (5 trades)Oct 2025: bought $0 (0 trades), sold $1 K (1 trades)OctNov 2025: bought $0 (0 trades), sold $71 K (1 trades)Dec 2025: bought $0 (0 trades), sold $133 K (1 trades)Jan 2026: bought $0 (0 trades), sold $681 K (5 trades)Jan 26Feb 2026: bought $0 (0 trades), sold $363 K (5 trades)Mar 2026: bought $0 (0 trades), sold $135 K (2 trades)May 2026: bought $0 (0 trades), sold $213 K (3 trades)MayJun 2026: bought $0 (0 trades), sold $847 K (11 trades)Jul 2026: bought $0 (0 trades), sold $828 K (5 trades)Sep 2026: bought $0 (0 trades), sold $297 K (5 trades)SepNov 2026: bought $34 K (1 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Abeona Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Faith L. CharlesDirectorBuy+15,000$2.290$34 K191,407Form 4
filed Vishwas SeshadriChief Executive Officer, DirectorSell-19,608$5.160$101 K1.29 MForm 4
filed Madhav VasanthavadaChief Commercial OfficerSell-4,902$5.160$25 K285,721Form 4
filed Brendan M. O'MalleySVP, Chief Legal OfficerSell-6,727$5.160$35 K421,226Form 4
filed Joseph Walter VazzanoChief Financial OfficerSell-9,191$5.160$47 K482,888Form 4
filed Mark AlvinoDirectorSell-15,000$5.860$88 K62,065Form 4
filed Joseph Walter VazzanoChief Financial OfficerSell-1,478$6.530$10 K492,079Form 4
filed Vishwas SeshadriChief Executive Officer, DirectorSell-67,971$6.960$473 K1.31 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Abeona Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
16.9 M
30.7% of shares · 21.67 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 75,205 shares at $4.56
  • : 12,899 shares at $4.55
  • : 1,283 shares at $4.45
  • : 1,153 shares at $4.31
  • : 9,601 shares at $4.40

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Abeona Therapeutics Inc. scorecard#

Passes 10 of the 18 checks that could be worked out: strongest in valuation (3 of 5), weakest in profitability (2 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation3 of 5
    • ✓P/E below its peers' median3.7×P/E 3.7× against Biotechnology's median of 17.5×.
    • ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median44.8×Price to sales 44.8× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-32.4%Free cash flow is -32.4% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield27.3%Earnings yield 27.3% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✓Earnings per share grew in the newest year1.01 vs -1.55Diluted EPS 1.01 in fiscal 2025 against -1.55 the year before (report's currency).
    • ✓Net income higher than five years earlier$71 M$71 M in fiscal 2025 against -$84 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability2 of 4
    • ✓Profitable in the newest year$71 MNet income $71 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✓Return on equity above 15%70.0%70.0% in fiscal 2025.
    • ✗Return on invested capital above 10%-127.2%-127.2% in fiscal 2025.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 6
    • ✓Short-term assets cover short-term liabilities6.9×Current ratio 6.93 at the end of fiscal 2025.
    • ✓Debt below equity0.1×Debt to equity 0.13 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $58 M at the end of fiscal 2025.
    • ✗Operating income covers interest five times-23.9×Operating income -23.9 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-2.50Z-score -2.50 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year61.1%Diluted shares up 61.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Abeona Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Abeona Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue5.8—3.51.43.010—3.00.80.9
Cost of revenue1.5—————————
Research and development2734312939r3049391711
Selling, general and administrative6530————————
General and administrative6530191722r2421201113
Operating expenses—6451529391776129—
Total costs and expenses9564—————612925
Operating income−89−64−47−51−90−81−77−58−28−24
Interest expense and finance costs3.74.20.40.73.7r4.1————
Other non-operating income (expense)0.41.22.90.1————0.52.0
Income before tax71−64————————
Income tax0.1——————000
Net income attributable to shareholders71−64−54−40−85−84−76−57−27−22
Earnings per share, basic1.34-1.55-2.53-5.53-21.57r-0.91-1.51-1.19-0.66-0.64
Earnings per share, diluted1.01-1.55-2.53-5.53-0.86-0.91-1.51-1.19-0.66-0.64
Shares, weighted average (basic)5341217.93.9————34
Shares, weighted average (diluted)6641217.9989350484234
Balance sheet
Cash and cash equivalents78231414331312919138r69
Short-term investments1137438381282—660—
Receivables6.1———3.0——0.10.10.1
Inventory5.5—————————
Other current assets1.31.10.70.42.4r2.73.13.82.70.2
Current assets205101565356r981328914169
Property, plant and equipment9.94.43.55.71211139.41.40.7
Right-of-use (leased) assets4.03.64.55.39.47.08.0———
Goodwill—————3232323232
Other intangible assets———01.41.536434.08.4
Total assets220109646480151223174179111
Accounts payable7.93.41.91.84.34.73.86.11.9r3.7
Debt due within a year125.9————————
Current liabilities3017137.8174239205.68.3
Long-term debt7.813————————
Lease liabilities (non-current)4.13.34.45.97.65.36.3———
Total liabilities6065493737r4945408.712
Retained earnings−742−813−750−695−656−571−486−410−360−332
Shareholders' equity15944152742r10317813417099
Total liabilities and equity220109646480151223174179111
Shares outstanding554627185.9r9684484740
Cash-flow statement
Depreciation and amortization2.52.02.33.13.34.67.82.40.70.8
Share-based compensation116.64.83.18.9r5.97.38.24.64.8
Cash from operating activities−76−56−37−43−66−35−63−39−23r−13
Capital expenditure−8.0−2.4−0.3−0.1−4.2−1.3−6.3−9.2−0.9−0.5
Intangible assets bought——————−0.2−1000
Cash from investing activities105−390.2−2466−8460−85−0.9−0.5
Debt issued—20————————
Shares issued171514138.1—17———
Cash from financing activities261043743251.91145.59243
Change in cash558.90.3−2425−117111−11969r29
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Abeona Therapeutics Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • License$3 M58%
  • Product(total)$2 M42%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Abeona Therapeutics Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$4.0 M
Vishwas Seshadri
Other top executives, average
$1.6 M
the CEO earned 2.6× this
$100 invested is now
$171
Abeona Therapeutics Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Vishwas Seshadri$4.0 M$4.0 M$1.6 M$171
2024Vishwas Seshadri$3.5 M$4.0 M$1.5 M$181
2023Vishwas Seshadri$2.8 M$3.5 M$1.3 M$163

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Abeona Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 2 · Directors and officers 4 · Material agreement 3 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10

Abeona Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Acquisition or sale completedMaterial agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreementNew debt8-K
Acquisition or sale completedResults announced8-K
Shareholder vote8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Abeona Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2015$14 MPrivate placement after listing$10 to $50 million17equitySEC
May 2015$10 MPrivate placement after listing$10 to $50 million2equity, optionsSEC
Oct 2012$10 MNo. 2$10 to $50 million1equitySEC
Nov 2011$6 MNo. 1$2 to $10 million14equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Abeona Therapeutics Inc. compares in Biotechnology

  • Market cap$261 M · higher than 49% of 726
  • Revenue$6 M · higher than 37% of 647
  • P/E ratio3.7× · lower than 89% of 100
  • Price / sales44.8× · lower than 19% of 339
  • Price / book1.6× · lower than 64% of 534
  • FCF yield-32.4% · higher than 33% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Abeona Therapeutics Inc.🇺🇸$261 M3.7×——
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Abeona Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Abeona Therapeutics Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Abeona Therapeutics Inc.? Suggest a correction